ClinicalTrials.gg
CompletedNCT02855684EDITION APUpdated Apr 25, 2022

Comparison of the Efficacy and Safety of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Insufficiently Controlled With Non-insulin Antidiabetic Therapy

A Phase 3 interventional study of Insulin glargine (U300) and Insulin glargine in Type 2 Diabetes Mellitus, sponsored by Sanofi. Completed at 54 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-04-25.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
604
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2 — 4 open to participants now, 6 under way, 1 of them phase 3. Insulin Glargine · Diabetes Mellitus, Type 2.

Enrollment
30th of 175
604 · median 253
Started
2016
with 7 others
Phase 3
60 of 176
1 open now
Registered
137th of 176
by date
Lead sponsor
82 of 176
Sanofi

Among the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2, this one is the 30th largest by enrollment of the 175 interventional ones that give a count, is one of 8 that started in 2016, is one of 60 in phase 3, and was the 137th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

4 of the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About Insulin Glargine

Insulin Glargine: first FDA approval 2000 (LANTUS SOLOSTAR), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

Primary Objective:

To compare the efficacy of insulin glargine (U300) and Lantus in terms of change of glycated hemoglobin A1c (HbA1c) from baseline to endpoint (scheduled at Month 6, Week 26) in patients with type 2 diabetes mellitus.

Secondary Objectives:

  • To compare insulin glargine (U300) and Lantus in terms of occurrence of hypoglycemia and nocturnal hypoglycemia.
  • To compare insulin glargine (U300) and Lantus in terms of reaching target HbA1c values (all and reaching target without hypoglycemia).
  • To compare insulin glargine (U300) and Lantus in terms of controlled plasma glucose (all and reaching target without hypoglycemia).
  • To compare the frequency of occurrence and diurnal distribution of hypoglycemia by category of hypoglycemia (documented symptomatic, asymptomatic, nocturnal, severe, probable and relative).
  • To assess the safety and tolerability of insulin glargine (U300).
  • To assess the development of anti-insulin glargine antibodies (AIA).
Read the detailed description

The total maximum study duration per patient will be 29 weeks that will consist of a 2-week screening period, 26-week treatment period, and a 2-day post-treatment safety follow-up period.

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients with type 2 diabetes mellitus inadequately controlled with non-insulin antihyperglycemic drug(s).
  • Signed written .

Exclusion criteria

Exclusion criteria:

  • Age \< legal age of adulthood.
  • \<7.0% (\<53 mmol/mol) or >11% (>97 mmol/mol) (at screening).
  • History of type 2 diabetes mellitus for less than 1 year before screening.
  • Less than 6 months before screening with non-insulin antihyperglycemic treatment.
  • Change in dose of non-insulin antihyperglycemic treatment in the last 3 month before screening.
  • Initiation of new glucose-lowering medications and/or weight loss drug in the last 3 months before screening visit and/or initiation of glucagon like peptide-1(GLP-1) receptor agonist in the last 6 months before screening visit.
  • Patients receiving only non-insulin antihyperglycemic drugs not approved for combination with insulin according to local labeling (Note: non-insulin antihyperglycemic drugs not approved for combination with insulin are to be discontinued at randomization).
  • Current or previous insulin use except for a maximum of 10 consecutive days (eg, acute illness, surgery) during the last one year prior to screening.
  • Severe hypoglycemia resulting in coma/seizures, and/or hospitalization for diabetic ketoacidosis in the last 6 months before screening visit.
  • Unstable proliferative diabetic retinopathy or any other rapidly progressive diabetic retinopathy or macular edema likely to require treatment (eg, laser, surgical treatment or injectable drugs) during the study period.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
604 participants (actual)

Study arms

  • Experimental
    Toujeo - insulin glargine (U300)

    Toujeo - Insulin glargine (U300) will be administered subcutaneously once in the evening on top of the non-insulin antihyperglycemic drugs for 29 weeks

    Drug: Insulin glargine (U300) · Drug: Non-insulin antihyperglycemic drugs

  • Active comparator
    Lantus - insulin glargine

    Lantus - Insulin glargine will be administered subcutaneously once in the evening on top of the non-insulin antihyperglycemic drugs for 29 weeks

    Drug: Insulin glargine · Drug: Non-insulin antihyperglycemic drugs

Interventions

  • Pharmaceutical form: solution Route of administration: subcutaneous

    Also known as: HOE901; Toujeo

  • Pharmaceutical form: solution Route of administration: subcutaneous

    Also known as: HOE901; Lantus

  • DrugNon-insulin antihyperglycemic drugs

    Pharmaceutical form: capsule/tablet Route of administration: oral

    Also known as: Non-insulin antihyperglycemic therapy

06

What researchers measure

Primary outcomes

  1. Change in HbA1c from baseline

    Time frame: Baseline, 6 months

Secondary outcomes

  1. Percentage (%) of patients with at least one hypoglycemia

    Time frame: Baseline, up to 6 months

  2. Percentage (%) of patients with at least one nocturnal hypoglycemia

    Time frame: Baseline, up to 6 months

  3. Percentage (%) of patients with HbA1c <7.0%

    Time frame: 6 months

  4. Percentage (%) of patients with HbA1c ≤6.5%

    Time frame: 6 months

  5. Percentage (%) of patients with Fasting Plasma Glucose (FPG) <100 mg/dL (5.6 mmol/L)

    Time frame: 6 months

  6. Percentage (%) of patients with FPG ≤120 mg/dL (6.7 mmol/L)

    Time frame: 6 months

  7. Percentage (%) of patients requiring rescue therapy

    Time frame: 6 months

  8. Change in fasting plasma glucose

    Time frame: Baseline, 6 months

  9. Change in 8-point Self-monitored Plasma Glucose (SMPG) profiles

    Time frame: Baseline, 6 months

  10. Change of mean 24-hour plasma glucose

    Time frame: Baseline, 6 months

  11. Change in variability of plasma glucose profile

    Time frame: Baseline, 6 months

  12. Change in daily basal insulin dose

    Time frame: Baseline, 6 months

07

Study locations

54 sites
  • Investigational Site Number 1560039
    Beijing, 100034, China
  • Investigational Site Number 1560001
    Beijing, 100044, China
  • Investigational Site Number 1560017
    Beijing, 100191, China
  • Investigational Site Number 1560003
    Beijing, 100730, China
  • Investigational Site Number 1560033
    Changchun, 130021, China
  • Investigational Site Number 1560016
    Changzhou, 213003, China
  • Investigational Site Number 1560049
    Changzhou, 213003, China
  • Investigational Site Number 1560006
    Fuzhou, 354200, China
  • Investigational Site Number 1560004
    Guangzhou, 510080, China
  • Investigational Site Number 1560036
    Guangzhou, 510080, China
  • Investigational Site Number 1560043
    Guangzhou, 510120, China
  • Investigational Site Number 1560014
    Guangzhou, 510515, China
  • Investigational Site Number 1560042
    Guiyang, 550004, China
  • Investigational Site Number 1560024
    Hangzhou, 310015, China
  • Investigational Site Number 1560046
    Hefei, 230001, China
  • Investigational Site Number 1560025
    Hohhot, 010017, China
  • Investigational Site Number 1560019
    Jinan, 250013, China
  • Investigational Site Number 1560027
    Lanzhou, 730000, China
  • Investigational Site Number 1560038
    Nanchang, 330006, China
  • Investigational Site Number 1560045
    Nanchang, 330006, China
  • Investigational Site Number 1560002
    Nanjing, 210008, China
  • Investigational Site Number 1560012
    Nanjing, 210011, China
  • Investigational Site Number 1560047
    Nanjing, 210029, China
  • Investigational Site Number 1560021
    Shanghai, 200040, China
  • Investigational Site Number 1560018
    Shanghai, 200240, China
  • Investigational Site Number 1560048
    Shenyang, 110004, China
  • Investigational Site Number 1560005
    Shenyang, 110022, China
  • Investigational Site Number 1560020
    Shenzhen, 518036, China
  • Investigational Site Number 1560013
    Siping, 136000, China
  • Investigational Site Number 1560031
    Tangshan, 063000, China
  • Investigational Site Number 1560023
    Tianjin, 300052, China
  • Investigational Site Number 1560044
    Tianjin, 300121, China
  • Investigational Site Number 1560009
    Xi'An, 710061, China
  • Investigational Site Number 1560034
    Xiamen, 361003, China
  • Investigational Site Number 1560010
    Xuzhou, 221002, China
  • Investigational Site Number 1560026
    Yueyang, 414000, China
  • Investigational Site Number 1560011
    Zhengzhou, 450052, China
  • Investigational Site Number 1560030
    Zhenjiang, 212001, China
  • Investigational Site Number 1560041
    Zhuzhou, 412007, China
  • Investigational Site Number 4100003
    Anyang, 431-070, Korea, Republic of
  • Investigational Site Number 4100005
    Busan, 602-739, Korea, Republic of
  • Investigational Site Number 4100010
    Gwangju, 61453, Korea, Republic of
  • Investigational Site Number 4100012
    Gyeonggi-Do, 11923, Korea, Republic of
  • Investigational Site Number 4100008
    Seoul, 01830, Korea, Republic of
  • Investigational Site Number 4100001
    Seoul, 03181, Korea, Republic of
  • Investigational Site Number 4100009
    Seoul, 06351, Korea, Republic of
  • Investigational Site Number 4100004
    Seoul, 110-744, Korea, Republic of
  • Investigational Site Number 4100006
    Seoul, 120-752, Korea, Republic of
  • Investigational Site Number 4100007
    Seoul, 138-878, Korea, Republic of
  • Investigational Site Number 4100002
    Wonju, 26426, Korea, Republic of
  • Investigational Site Number 1580001
    Taichung, 40447, Taiwan
  • Investigational Site Number 1580004
    Taipei, 104, Taiwan
  • Investigational Site Number 1580003
    Taipei, 11031, Taiwan
  • Investigational Site Number 1580002
    Taipei, 220, Taiwan
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2016, a primary completion of Aug 2018 and a completion of Aug 2018. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 2, 2016
First posted
Aug 4, 2016
Start
Aug 24, 2016
Primary completionActual
Aug 6, 2018
CompletionActual
Aug 6, 2018
Last update
Apr 25, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 25, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02855684
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Aug 4, 2016
Start date
Aug 24, 2016
Primary completion
Aug 6, 2018
Completion
Aug 6, 2018
Last update
Apr 25, 2022

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin Glargine

Start the discussion